• Publications
  • Influence
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
TLDR
The combination of tenofovir DF and emtricitabineplus efavirenz fulfilled the criteria for noninferiority to a fixed dose of zidovudine and lamivudine plus efvirenz and proved superior in terms of virologic suppression, CD4 response, and adverse events resulting in discontinuation of the study drugs.
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
TLDR
The availability of new antiretroviral drugs has expanded treatment choices and the importance of adherence, emerging long-term complications of therapy, recognition and management of antireTroviral failure, and new monitoring tools are addressed.
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.
TLDR
Because of increased awareness of the activity and toxicity of current drugs, the threshold for initiation of therapy has shifted to a later time in the course of HIV disease, however, the optimal time to initiate therapy remains imprecisely defined.
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.
TLDR
The virologic target for patients with treatment failure is now a plasma HIV-1 RNA level below 50 copies/mL, making delivery of state-of-the-art care challenging.
Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome
TLDR
The MASRI provides a means of measuring patient adherence that is valid when compared with objective measures and treatment outcome and is inversely associated with viral load.
Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection.
TLDR
It is shown that the CD161++ /MAIT cell population is significantly decreased in early HIV infection and fails to recover despite otherwise successful treatment, and this loss may impact mucosal defense and could be important in susceptibility to specific opportunistic infections in HIV.
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
TLDR
The data demonstrate a favorable safety profile for tenofovir DF in the treatment of adults with HIV infection, and risk factors for development of nephrotoxicity can be identified and may be useful in managing those patients at greatest risk.
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.
TLDR
Since the introduction of HAART, there has been a significantly increased risk of NADCs, which has now stabilized, and a number of factors are associated with this increased risk, including HAART use.
...
...